Technology | August 11, 2009

Pathway Medical Technologies Introduces Jetstream G2 NXT Atherectomy Catheter

August 11, 2009 – Pathway Medical Technologies Inc. today introduced the 7 French compatible version of its peripheral atherectomy catheter, the Jetstream G2 NXT.

The catheter is based on the company’s catheter technology capable of treating the entire spectrum of disease found in patients suffering from peripheral artery disease (PAD), including hard and soft plaque, calcium, fibrotic lesions and thrombus. The 7 Fr. compatibility allows physicians to use Jetstream G2 NXT in the treatment of PAD in a more diverse patient population, significantly expanding the number of patients who can now benefit from this innovative technology, the company said.

“The 7 Fr. compatible Jetstream G2 NXT is nearly identical to Jetstream G2, but has the advantages associated with smaller sheath technology,” said Dr. Robert Bersin at Seattle Cardiology. “As such, it expands my ability to treat more anatomies and patients with varying degrees of PAD.”

Jetstream G2 NXT is a peripheral atherectomy catheter designed to remove all kinds of artery-clogging plaque in the lower limbs of patients. This innovative and minimally invasive solution clears blockages in the peripheral vasculature, restores blood flow and effectively treats PAD.

Jetstream G2 NXT consists of a sterile, single-use catheter and control pod and a reusable, compact console that mounts to a standard I.V. stand. The catheter has an expandable cutting tip that safely debulks and preemptively removes both hard and soft plaque, as well as calcium, thrombus and fibrotic lesions. A highly efficient aspiration port located just proximal to the cutting blades continually removes excised tissue and thrombus from the treatment site to a collection bag located on the console. The distal portion of the catheter also possesses infusion ports that provide continuous infusion of sterile saline during the atherectomy procedure. Active aspiration is a safety feature that minimizes the risk of distal embolization.

For more information:

Related Content

Interventional cardiology, cath lab technology, TCT, transcatheter cardiovascular therapeutics
Feature | Cath Lab| October 27, 2016 | Dave Fornell
The volume of information attendees receive at the annual Transcatheter Cardiovascular Therapeutics (TCT) interventio
Avinger, Pantheris atherectomy catheter, OCT, Lumivascular technology, expanded FDA indication, diagnostic imaging device
News | Atherectomy Devices| October 20, 2016
Avinger Inc. recently announced that the company has received expanded indications from the U.S. Food and Drug...
Society for Vascular Surgery, SVS, new PAD reporting standards, peripheral artery disease
News | Peripheral Arterial Disease (PAD)| October 12, 2016
October 12, 2016 — The Society for Vascular Surgery (SVS) has released new reporting standards focused on endovascula
Medtronic, FDA clearance, TrailBlazer peripheral angled support catheter, PAD, peripheral artery disease
Technology | Peripheral Arterial Disease (PAD)| October 12, 2016
Medtronic plc announced recently that the U.S. Food and Drug Administration (FDA) has cleared the TrailBlazer angled...
Mercator MedSystems, Bullfrog Micro-Infusion Device, DANCE trial, VIVA 2016, 13-month results
News | Peripheral Arterial Disease (PAD)| October 07, 2016
Mercator MedSystems recently announced that 13-month data from the DANCE trial was presented during a late-breaking...
Bard, Lutonix 014 DCB, drug-coated balloon, six-month endpoint, FDA IDE trial
Technology | Drug-Eluting Balloons| September 26, 2016
C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
Shockwave medical, lithoplasty
News | Cath Lab| September 19, 2016
September 19, 2016 — Shockwave Medical announced positive clinical results from the pooled DISRUPT PAD Study, a singl
Sponsored Content | Videos | Peripheral Arterial Disease (PAD)| September 16, 2016
Shockwave Medical’s Lithoplasty System uses ultrasonic waves to treatment calcified plaque in patients with periphera
Overlay Init